Premium
United we stand, divided we fall. Multicentre standardization of measurable residual disease assessment in acute leukaemia is the way forward
Author(s) -
Chatterjee Gaurav,
Patkar Nikhil
Publication year - 2023
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/bjh.18533
Subject(s) - standardization , minimal residual disease , medicine , flow cytometry , harmonization , residual , disease , oncology , pediatrics , immunology , leukemia , computer science , algorithm , physics , acoustics , operating system
Assessment of measurable residual disease (MRD) using multiparameter flow cytometry in precursor B‐cell acute lymphoblastic leukaemia (ALL) is routine. However, studies on the harmonization of laboratory techniques as well as on the interpretation of results are limited. Here, Ikoma‐Colturato and colleagues from Brazil demonstrate multicentric standardization of B‐ALL MRD using EuroFlow protocols. Commentary on: Ikoma‐Colturato et al., Multicentric standardization of minimal/measurable residual disease in B‐cell precursor acute lymphoblastic leukaemia using next‐generation flow cytometry in a low/middle‐level income country. Br J Haematol 2023;200:381‐384.